Business Wire

Joe Kiani Provides Keynote at the 5th Annual Global Ministerial Summit on Patient Safety

27.2.2023 23:33:00 EET | Business Wire | Press release

Share

In a keynote address at the Fifth Global Ministerial Summit on Patient Safety, Joe Kiani, founder of the Patient Safety Movement Foundation (PSMF), called for hospitals around the world to show greater transparency in reporting medical errors and preventable deaths. He also stressed the importance of aligned incentives, so providers are paid on quality of care rather than quantity and the adoption of Actionable Evidence-Based Practices addressing the known causes of harm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230227005765/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Joe Kiani Provides Keynote at the 5th Annual Global Ministerial Summit on Patient Safety (Photo: Business Wire)

“We need not just access to healthcare, it has to be safe, it has to be dignified,” said Kiani. “To get there, we have to create self-governing actions. If we can agree on the medical errors that can be prevented through evidence-based practices, those then can be tracked by every hospital. And they could report every year, every quarter, on their website publicly, the number of harms they have for each of those errors.”

Transparency, Kiani argued, is critical because publicly revealing data on preventable medical errors helps to accelerate the pace of change.

In countries where healthcare is at least partially subsidized by the government, Kiani suggested introducing major financial incentives for hospitals to be more transparent and active in patient safety by implementing evidence-based practices for preventing errors.

“In my country, half of the care is paid for by the Government. Medicare and Medicaid pays for more than half the care in every hospital,” he said. “So therefore, they could mandate that to get that reimbursement, they want transparency, and that they will tie their performance to the payment. So if hospitals have zero medical errors, zero preventable deaths, they don't have to do anything. But if someone is harmed, and those evidence-based practices were not in place, they should not get paid. This becomes a way that every board of directors of every hospital will expect their management to implement evidence-based practices.”

As an example of how this can work, Kiani cited his time on the board of directors of Children's Hospital of Orange County (CHOC), California. “When I began at CHOC, I was happy to see they were looking at quality,” he said. “They were looking at medical errors, but they were comparing themselves to their colleagues, and if they were lower in error rate than others, that was considered a job well done. And I challenged them that shouldn't the goal be zero? To their credit, they accepted the challenge, and they went one step further, they tied the bonuses of the faculty to zero. Something incredible occurred at the next meeting, we went from hoping for zero, to planning for zero.”

“I want you all to take action out of kindness!” concluded Joe Kiani.

The Global Ministerial Summit on Patient Safety is an annual event that brings together ministers, high-level representatives, and experts from around the world. This year’s summit was hosted by President Alain Berset and the distinguished speakers included; Tedros Adhanom Ghebreyesus, Director-General, World Health Organization; Professor Didier Pittet, Professor of Medicine at the University of Geneva; Dr. Anthony Staines, Patient Safety Program Director of Vaud Hospital Federation in Switzerland; Professor Dr. Phil Lauren Clark, Professor of Implementation Science in Health Care; and Professor Sir Liam Donaldson, WHO Patient Safety Envoy.

This year the Patient Safety Movement Foundation will hold its 10th Annual World Patient Safety, Science & Technology Summit on June 1st and 2nd in Newport Beach, California.

ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP is available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release

VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye